BRPI0513186A - composição medicinal para a administração oral - Google Patents

composição medicinal para a administração oral

Info

Publication number
BRPI0513186A
BRPI0513186A BRPI0513186-3A BRPI0513186A BRPI0513186A BR PI0513186 A BRPI0513186 A BR PI0513186A BR PI0513186 A BRPI0513186 A BR PI0513186A BR PI0513186 A BRPI0513186 A BR PI0513186A
Authority
BR
Brazil
Prior art keywords
oral administration
medicinal composition
composition
loxoprofen
reduced risk
Prior art date
Application number
BRPI0513186-3A
Other languages
English (en)
Inventor
Yasuhiro Torizumi
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35783918&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0513186(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of BRPI0513186A publication Critical patent/BRPI0513186A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

COMPOSIçãO MEDICINAL PARA A ADMINISTRAçãO ORAL. Uma composição contendo loxoprofeno para a administração oral, que apresenta um risco reduzido em causar distúrbios da mucosa gástrica. A composição para a administração oral compreende loxoprofeno e um agente antiácido.
BRPI0513186-3A 2004-07-13 2005-07-12 composição medicinal para a administração oral BRPI0513186A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004205934 2004-07-13
PCT/JP2005/012798 WO2006006577A1 (ja) 2004-07-13 2005-07-12 ロキソプロフェンを含有する経口投与用組成物

Publications (1)

Publication Number Publication Date
BRPI0513186A true BRPI0513186A (pt) 2008-04-29

Family

ID=35783918

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513186-3A BRPI0513186A (pt) 2004-07-13 2005-07-12 composição medicinal para a administração oral

Country Status (5)

Country Link
JP (6) JP2012051949A (pt)
KR (1) KR20070034576A (pt)
CN (1) CN101014333A (pt)
BR (1) BRPI0513186A (pt)
WO (1) WO2006006577A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008195705A (ja) * 2007-01-15 2008-08-28 Daiichi Sankyo Healthcare Co Ltd ロキソプロフェン含有経口用組成物
JP5681430B2 (ja) * 2009-09-30 2015-03-11 興和株式会社 ロキソプロフェン含有医薬組成物
JP2011132226A (ja) * 2009-11-27 2011-07-07 Kowa Co ロキソプロフェン含有医薬組成物及び該組成物を含む医薬製剤
JP6139050B2 (ja) * 2010-08-27 2017-05-31 興和株式会社 医薬
EP3916112B1 (en) 2019-03-13 2024-01-24 JFE Steel Corporation Steel plate and method for manufacturing the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2704721B2 (ja) * 1987-02-12 1998-01-26 ライオン株式会社 イブプロフエン製剤
JP3122748B2 (ja) * 1991-11-29 2001-01-09 ライオン株式会社 イブプロフェン含有解熱鎮痛剤
JP4113267B2 (ja) * 1997-04-03 2008-07-09 日医工株式会社 ロキソプロフェンナトリウム含有錠剤
JP4936579B2 (ja) * 1997-09-05 2012-05-23 第一三共株式会社 ロキソプロフェン含有医薬製剤
JP2001172175A (ja) * 1999-12-14 2001-06-26 Taisho Pharmaceut Co Ltd 風邪用組成物
JP2001181190A (ja) * 1999-12-22 2001-07-03 Takeda Chem Ind Ltd 医薬組成物
JP2001199882A (ja) * 2000-01-20 2001-07-24 Taisho Pharmaceut Co Ltd 感冒・鼻炎用組成物
JP2002226366A (ja) * 2001-02-02 2002-08-14 Yuutoku Yakuhin Kogyo Kk 外用貼付剤
US20040147606A1 (en) * 2001-05-25 2004-07-29 Yoichi Onuki Medicinal compositions
JP4614640B2 (ja) * 2002-07-04 2011-01-19 第一三共株式会社 解熱剤組成物
JP2004161667A (ja) * 2002-11-13 2004-06-10 Saiseido Yakuhin Kk 生薬配合医薬組成物

Also Published As

Publication number Publication date
JP2012051949A (ja) 2012-03-15
JP6106727B2 (ja) 2017-04-05
JP2016056195A (ja) 2016-04-21
JP6192751B2 (ja) 2017-09-06
JP2014098036A (ja) 2014-05-29
WO2006006577A1 (ja) 2006-01-19
KR20070034576A (ko) 2007-03-28
JP2016027058A (ja) 2016-02-18
JP2012051950A (ja) 2012-03-15
JP5833157B2 (ja) 2015-12-16
JP2014132038A (ja) 2014-07-17
CN101014333A (zh) 2007-08-08

Similar Documents

Publication Publication Date Title
CY1121350T1 (el) Απο του στοματος φαρμακοτεχνικες μορφες αναλογων κυτιδινης και μεθοδοι χρησης αυτων
MX2009010289A (es) Composiciones para administracion nasal.
DE602004019053D1 (de) Titrationsdosierschema für kontrolliert freigesetztes tramadol
AR045972A1 (es) Formulaciones de tramadol de liberacion sostenida con eficacia de 24 horas
EP2248519A3 (en) Non-mucoadhesive film dosage forms
PT1083879E (pt) Metodos e dispositivos para proporcionar uma terapia de drogas prolongada
BR9916224A (pt) Forma de dosagem farmacêutica oral, processos para a manufatura de uma forma de dosagem fixa, para o tratamento e a profilaxia de distúrbios gastrintestinais e para evitar efeitos colaterias gastrintestinais, uso de uma forma de dosagem, combinação, e, embalagem tipo ampola
BR0316027A (pt) Formulações de toxina botulina para administração oral
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
ECSP045029A (es) Composiciones de valdecoxib de disgregación intraoral
MX2010002498A (es) Metodos para tratar o prevenir la infeccion del tracto respiratorio que comprende la administracion de colecalciferol.
CY1112738T1 (el) Μια συνδυασμενη συνθεση που περιεχει ιβουπροφαινη και παρακεταμολη
AR065392A1 (es) Metodos para el tratamiento por inhalacion de una enfermedad o estado respiratorio
ITMI20041317A1 (it) Formulazioni farmaceutiche per la somministrazione sicura di farmaci utilizzati nel trattamento della tossicodipendenza e procedimento per il loro ottenimento
PE20060588A1 (es) Composiciones farmaceuticas que contienen flibanserina
BR0208421A (pt) Formulação farmacêutica para administração a um paciente através das mucosas, dose farmacêutica diária, dispersão sólida, uso de pvp em dispersão sólida com 4'-ciano-alfa', alfa', alfa'-trifluoro-3-(4-fluoro fenilsulfonil)-2-hidróxi-2-metilpropiono-m-toluidet o, e, métodos para aumentar a estabilidade em armazenagem, a biodisponibilidade da droga e para reduzir a variação de concentrações de plasma do 4'-ciano-alfa', alfa', alfa',-trifluoro-3-(4-fluorofenilsulfonil)-2-hidróxi-2 -metilpropiono-m-toluideto entre pacientes
MX2022014199A (es) Usos y formulaciones de los cannabinoides.
AR057946A1 (es) Formulacion de zonisamida de liberacion sostenidda
CL2007002875A1 (es) Composicion farmaceutica recubierta por una pelicula que comprende capecitabina y al menos un disgregante, util en el tratamiento del cancer para pacientes que tienen dificultad para tragar las formas de dosificacion solidas orales.
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
BRPI0605214A (pt) composição farmacêutica orodispersável para administração por via mucosa oral ou sublingual de agomelatina
BR9916575A (pt) Composição farmacêutica de liberação controlada com mesilato de tilidina como substância-ativa
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
EA200702522A1 (ru) Система доставки лекарств в полость рта и способы ее применения
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2143 DE 31/01/2012.